AR044852A1 - Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina - Google Patents

Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina

Info

Publication number
AR044852A1
AR044852A1 ARP040102163A ARP040102163A AR044852A1 AR 044852 A1 AR044852 A1 AR 044852A1 AR P040102163 A ARP040102163 A AR P040102163A AR P040102163 A ARP040102163 A AR P040102163A AR 044852 A1 AR044852 A1 AR 044852A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
ala
amino acid
formula
analog
Prior art date
Application number
ARP040102163A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33554159&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044852(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0314695A external-priority patent/GB0314695D0/en
Priority claimed from GB0325388A external-priority patent/GB0325388D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR044852A1 publication Critical patent/AR044852A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form

Abstract

Reivindicación 1: Una composición farmacéutica para administración parenteral que comprende un análogo de somatostatina que comprende la secuencia de aminoácido de la fórmula (19 -(D/L)Trp-Lys-X1-X2- en donde X1 es un radical de la fórmula (2) o (3) en donde R1 es fenilo opcionalmente sustituido, R2 es -Z1-CH2-R1, -CH2-CO-O-CH2-R1, o como se muestra en los restos de fórmulas (4) en donde Z1 es O u S, y X2 es un alfa-aminoácido que tiene un residuo aromático en la cadena lateral de Calfa, o una unidad de aminoácido seleccionada de Dab, Dpr, Dpm, His, (Bzl)HyPro, tienil-Ala, ciclohexil-Ala y t-butil-Ala, el residuo Lys de dicha secuencia correspondiente al residuo Lys9 de la somatostatina-14 nativa. Reivindicación 2: Una composición de acuerdo con la reivindicación 1, en donde el análogo de somatostatina es un compuesto de la fórmula (5) en donde la configuración en C-2 es (R) o (S) o una mezcla de los mismos, y en done R es NR1R2-alquileno C2-6 o guanidina-alquileno C2-6, y cada uno de R1 y R2 independientemente es H o alquilo C1-4 en forma libre, forma de sal o forma protegida. Reivindicación 3: Un compuesto de acuerdo con la reivindicación 1 o 2, en donde el compuesto del análogo de somatostatina está en la forma de la di-sal de aspartato. Reivindicación 7: El uso de una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 6, para la preparación de un medicamento para acromegalia o cáncer.
ARP040102163A 2003-06-24 2004-06-22 Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina AR044852A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314695A GB0314695D0 (en) 2003-06-24 2003-06-24 Organic compounds
GB0325388A GB0325388D0 (en) 2003-10-30 2003-10-30 Organic compounds

Publications (1)

Publication Number Publication Date
AR044852A1 true AR044852A1 (es) 2005-10-05

Family

ID=33554159

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102163A AR044852A1 (es) 2003-06-24 2004-06-22 Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina

Country Status (32)

Country Link
US (3) US20070093412A1 (es)
EP (1) EP1648934B1 (es)
JP (1) JP4746541B2 (es)
KR (1) KR101124136B1 (es)
AR (1) AR044852A1 (es)
AT (1) ATE438659T1 (es)
AU (1) AU2004251866B2 (es)
BR (1) BRPI0411820B8 (es)
CA (1) CA2529449C (es)
CL (1) CL2004001579A1 (es)
CO (1) CO5650225A2 (es)
CY (1) CY1109444T1 (es)
DE (1) DE602004022420D1 (es)
DK (1) DK1648934T3 (es)
EC (1) ECSP056237A (es)
ES (1) ES2328144T3 (es)
HK (1) HK1089776A1 (es)
HR (1) HRP20090571T1 (es)
IL (1) IL172329A (es)
IS (1) IS2705B (es)
MA (1) MA27862A1 (es)
MX (1) MXPA05013821A (es)
MY (1) MY145375A (es)
NO (1) NO330706B1 (es)
NZ (1) NZ544157A (es)
PE (1) PE20050285A1 (es)
PL (1) PL1648934T3 (es)
PT (1) PT1648934E (es)
RU (1) RU2355418C2 (es)
SI (1) SI1648934T1 (es)
TW (1) TWI361194B (es)
WO (1) WO2005000893A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2224947T3 (pl) 2007-11-28 2015-08-31 Novartis Ag Zastosowanie analogów somatostatyny w leczeniu oponiaka
WO2009071460A2 (en) * 2007-12-03 2009-06-11 Italfarmaco Spa New non-selective somatostatin analogues
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
KR20160062023A (ko) * 2013-09-30 2016-06-01 오노 야꾸힝 고교 가부시키가이샤 소마토스타틴 수용체 작동 활성을 갖는 화합물 및 그 의약 용도
CN104447962B (zh) * 2014-12-29 2018-07-17 成都圣诺生物科技股份有限公司 一种合成帕瑞肽的方法
GB201816637D0 (en) 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
DE3264693D1 (en) * 1981-12-24 1985-08-14 Ciba Geigy Ag Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
US4612366A (en) * 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
JPH02111A (ja) * 1987-08-03 1990-01-05 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド製剤
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
JP2641755B2 (ja) 1988-01-29 1997-08-20 住友製薬株式会社 コントロールリリース製剤
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
ES2158897T3 (es) 1993-06-23 2001-09-16 Diatide Inc Peptidos radiomarcados derivados de somatostatina y utilizados en procedimientos de formacion de imagenes y terapeuticos.
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
ES2167189B1 (es) 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP2310042B1 (en) * 2008-07-08 2012-12-05 Novartis AG Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia

Also Published As

Publication number Publication date
TW200514789A (en) 2005-05-01
SI1648934T1 (sl) 2010-01-29
JP4746541B2 (ja) 2011-08-10
IS2705B (is) 2010-12-15
MY145375A (en) 2012-01-31
EP1648934B1 (en) 2009-08-05
US20090137462A1 (en) 2009-05-28
RU2355418C2 (ru) 2009-05-20
NZ544157A (en) 2008-07-31
NO20060375L (no) 2006-01-24
AU2004251866A1 (en) 2005-01-06
PL1648934T3 (pl) 2010-01-29
EP1648934A2 (en) 2006-04-26
BRPI0411820B8 (pt) 2021-05-25
WO2005000893A2 (en) 2005-01-06
BRPI0411820B1 (pt) 2019-06-25
US20130035286A1 (en) 2013-02-07
ECSP056237A (es) 2006-04-19
CL2004001579A1 (es) 2005-05-20
AU2004251866B2 (en) 2008-06-12
MXPA05013821A (es) 2006-02-28
CY1109444T1 (el) 2014-08-13
CA2529449C (en) 2012-05-15
US20070093412A1 (en) 2007-04-26
ATE438659T1 (de) 2009-08-15
TWI361194B (en) 2012-04-01
ES2328144T3 (es) 2009-11-10
IL172329A (en) 2013-12-31
RU2006101720A (ru) 2007-08-10
CA2529449A1 (en) 2005-01-06
WO2005000893A3 (en) 2005-04-07
KR20060030052A (ko) 2006-04-07
DK1648934T3 (da) 2009-10-26
CO5650225A2 (es) 2006-06-30
IS8247A (is) 2006-01-20
US8299209B2 (en) 2012-10-30
KR101124136B1 (ko) 2012-03-21
IL172329A0 (en) 2009-02-11
JP2007536195A (ja) 2007-12-13
DE602004022420D1 (de) 2009-09-17
PE20050285A1 (es) 2005-06-09
MA27862A1 (fr) 2006-04-03
PT1648934E (pt) 2009-10-23
HK1089776A1 (en) 2006-12-08
NO330706B1 (no) 2011-06-20
BRPI0411820A (pt) 2006-08-08
HRP20090571T1 (en) 2009-11-30

Similar Documents

Publication Publication Date Title
AR109033A2 (es) Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso
ECSP055774A (es) Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica
ATE549028T1 (de) Stabile analoga von glp-1
DE60045524D1 (de) Ein Huhn GnRH-II Analog zur Verwendung in der Reduktion des Tumorzellwachstums
BRPI0407001A (pt) Método para aumentar a estabilidade de uma proteìna purificada, uso de uma proteìna ligante sìtio-especìfica ativa, método para aumentar a produção de uma proteìna recombinante e composição farmacêutica
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
SG10201909675QA (en) Peptide vaccines for cancers expressing tumor-associated antigens
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
AR091866A1 (es) Analogos del glucagon
PA8551001A1 (es) Nuevos compuestos
AR014886A1 (es) 4,5-diarilimidazoles 2-substituidos, composiciones farmaceuticas que los contienen y su uso para la manufactura de medicamentos
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
AR067002A1 (es) Emulsiones de alta fase interna estables y composiciones que las comprenden
AR039352A1 (es) Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5.
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
BR0314450A (pt) Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
BR0009847A (pt) Kit de partes, método de preparação de um kit de partes, formulação farmacêutica, método de tratamento de uma condição na qual inibição de trombina é requerida ou desejada, e, uso de um inibidor de trombina, ou de um derivado farmaceuticamente aceitável do mesmo
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
AR044852A1 (es) Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
MX2020008096A (es) Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
SE9904421D0 (sv) New compounds
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
BR0302496A (pt) Composições farmacêuticas com atividade antibiótica

Legal Events

Date Code Title Description
FC Refusal